| Detailed information |
|---|
| CancerLivER ID | 2590 |
| Biomarker | MPV17, EST, GZMB, ITGA6, EST, CENPC1, EST, SPP1, RTF1, CYB5-M, P4HA2, DNMBP, EST, DNAJB4, PRH1, STK23, TCF2, POSTN, SPP1, WIZ, OSMR, EST, ILIA, CD44, EST, MUC6, MTHFD2, ANXA2, PCSK2, RBP1, EST, ITGA6, APRT, PDUM3, TPM2, RNASE3, OSMR, GRK1, SLC14A, FETUB, ANXA2P1, UGT2B15, EST, KIAA0703, AKAP10, AVPR |
| Biomarker Name/Symbol (given in Publication) | MPV17, EST, GZMB, ITGA6, EST, CENPC1, EST, SPP1, RTF1, CYB5-M, P4HA2, DNMBP, EST, DNAJB4, PRH1, STK23, TCF2, POSTN, SPP1, WIZ, OSMR, EST, ILIA, CD44, EST, MUC6, MTHFD2, ANXA2, PCSK2, RBP1, EST, ITGA6, APRT, PDUM3, TPM2, RNASE3, OSMR, GRK1, SLC14A, FETUB, ANXA2P1, UGT2B15, EST, KIAA0703, AKAP10, AVPR2 |
| Biomolecule | RNAs |
| Subject | Human |
| Degree of Validity | Potential progostic marker for Extrahepatic recurrence in HCC; but not validated on indpendent dataset |
| Experimental Condition | Extrahepatic recurrence (EHR) v/s Early intrahepatic recurrence (IHR) |
| Cancer type | Hepatocellular carcinoma |
| Regulation | Genes associated with EHR of HCC |
| Level of significance | P< 0.05 |
| Source | Tissue |
| PMID | 17016605 |
| Type of Biomarker | Prognostic |
| Pathway | Cell adhesion, Signal transduction, Cell proliferation, metabolic pathways, immune response and molecular transport |
| Cohort | 76 HCC samples : 35 HCC for recurrence (5 had extrahepatic metastases at surgery, and 5 had EHR after curative surgery. These 10 patients were classified as the EHR group. The remaining 25 patients, who had no EHR during the follow-up period, were classified as the non-EHR group). |
| Sensitivity | NA |
| Specificity | NA |
| Accuracy | NA |
| AUC | NA |
| Disease | Extrahepatic recurrence (EHR) v/s Early intrahepatic recurrence (IHR) |
| Year of Publication | 2006 |
| Clinical trial | NO |
| Clinical trial (NCT Number) | NA |